tbuckley/cabot-search huggingface dataset:
Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: Progress 2001–2006
Authors: Peter M. Fischer
Journal: Medicinal Research Reviews (2006)

Abstract Cell delivery vectors (CDVs) are short amphipathic and cationic peptides and peptide derivatives, usually containing multiple lysine and arginine residues. They possess inherent membrane activity and can be conjugated or complexed with large impermeable macromolecules and even microscopic particles to facilitate cell entry. Various mechanisms have been proposed but it is now becoming clear that the main port of entry into cells of such CDV constructs involves adsorptive‐mediated endocytosis rather than direct penetration of the plasma membrane. It is still unclear, however, how and to what extent CDV constructs are capable of exiting endosomal compartments and reaching their intended cellular site of action, usually the cytosol or the nucleus. Furthermore, although many CDVs can mediate cellular uptake of their cargo and appear comparatively non‐toxic to cells in tissue culture, the utility of CDVs for in vivo applications remains poorly understood. Whatever the mechanisms of cell entry and disposition, the overriding question as far as potential pharmacological application of CDV conjugates is concerned is whether or not a therapeutic margin can be achieved by their administration. Such a margin will only result if the intracellular concentration in the target tissues necessary to elicit the biological effect of the CDV cargo can be achieved at systemic CDV exposure levels that are non‐toxic to both target and bystander cells. It is proposed that the focus of CDV research now be shifted from mechanistic in vitro studies with labeled but otherwise unconjugated CDVs to in vivo pharmacological and toxicological studies using CDV‐derivatized and other cationized forms of inherently non‐permeable macromolecules of true therapeutic interest. © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 6, 755–795, 2007
Detection of Gilbert's Syndrome in Patients with Hemolysis
Authors: Paul D. Berk, Terrence F. Blaschke
Journal: Annals of Internal Medicine (1972)

Patients with Gilbert's syndrome have a characteristically abnormal pattern of radiobilirubin kinetics. Some patients with hemolysis have a similar abnormality. Demonstration of the Gilbert's type of hepatic defect in such patients previously has required the use of radiobilirubin clearance studies, which are not readily available. Accordingly, we have derived an equation that expresses the predicted range for the plasma concentration of unconjugated bilirubin, in patients with normal hepatic bilirubin clearance, as a function of the total red-cell volume and red-cell half-life, both of which may be determined from a single injection of chromium-51. This equation permits recognition—from radiochromium studies alone—of those patients who have both hemolysis and Gilbert's syndrome, since in such patients the plasma concentration of unconjugated bilirubin will exceed the predicted limits.
Plasma metalloproteinase levels are dysregulated in signal transducer and activator of transcription 3 mutated hyper-IgE syndrome
Authors: Vibhav Sekhsaria, Lori E. Dodd, Amy P. Hsu, Jennifer R. Heimall, Alexandra F. Freeman, Li Ding, Steven M. Holland, Gulbu Uzel
Journal: Journal of Allergy and Clinical Immunology (2011)
Mesenchymal stem cells express serine protease inhibitor to evade the host immune response
Authors: Najib El Haddad, Dean Heathcote, Robert Moore, Sunmi Yang, Jamil Azzi, Bechara Mfarrej, Mark Atkinson, Mohamed H. Sayegh, Jeng-Shin Lee, Philip G. Ashton-Rickardt, Reza Abdi
Journal: Blood (2010)
Chfr is required for tumor suppression and Aurora A regulation
Authors: Xiaochun Yu, Katherine Minter-Dykhouse, Liviu Malureanu, Wei-Meng Zhao, Dongwei Zhang, Carolin J Merkle, Irene M Ward, Hideyuki Saya, Guowei Fang, Jan van Deursen, Junjie Chen
Journal: Nature Genetics (2005)
Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis
Authors: Ebru Erbay, Vladimir R Babaev, Jared R Mayers, Liza Makowski, Khanichi N Charles, Melinda E Snitow, Sergio Fazio, Michelle M Wiest, Steven M Watkins, MacRae F Linton, Gökhan S Hotamisligil
Journal: Nature Medicine (2009)
P341 NON-INVASIVE IMAGING OF KUPFFER CELL STATUS USING RADIOLABELLED MANNOSYLATED ALBUMIN
Authors: V. Mahajan, S. Hartimath, R. Comley, M. Stefan-Gueldner, A. Roth, K. Poelstra, C. Reker-Smit, J. Kamps, R. Dierckx, E. de Vries
Journal: Journal of Hepatology (2014)
Clinical Evaluation of Dicumarinyl Derivatives with a Metabolic Study of the Radioactively Labeled Anticoagulants in Animals
Authors: ERIC P. HAUSNER, CHARLES L. SHAFER, MARION CORSON, OGDEN JOHNSON, THEODORE TRUJILLO, WRIGHT LANGHAM
Journal: Circulation (1951)

The common use of dicumarinyl derivatives for the treatment of thromboembolic diseases justifies further clinical evaluation of dicumarol and 4,4'-dihydroxydicumarinyl ethyl acetate [Pelentan, Tromexan, 3,3'-carboxymethylenebis (4-hydroxycoumarin) ethyl ester.] The need for a more thorough understanding of the pharmacodynamic action of dicumarinyl anticoagulants has prompted a study of their gross metabolism in animals, using C 14 -labeled materials.
Minor Transplacental Passage of Fondaparinux in Vivo
Authors: Carl-Erik H. Dempfle
Journal: New England Journal of Medicine (2004)

To the Editor: Low-molecular-weight heparin remains the anticoagulant of choice for pregnant women with previous thromboembolic events. Fondaparinux (Arixtra, Sanofi-Synthelabo) is a chemically synthesized derivative of the natural pentasaccharide sequence that mediates the interaction of heparin with antithrombin.1 It has been recommended for prophylaxis against thromboembolism after hip or knee surgery.2,3 My colleagues and I have treated five pregnant patients in whom anticoagulant therapy was indicated and who had severe cutaneous allergic reactions to low-molecular-weight heparin with fondaparinux at a dose of 2.5 mg per day. No allergic reactions at injection sites, thromboembolic events, or abnormal bleeding was observed. . . .
Chile votes to ban thiomersal in vaccines despite opposition from doctors and scientists
Authors: S. Arie
Journal: BMJ (2014)

Chile’s congress has voted to ban the use of vaccines that contain the preservative thiomersal, after a strong campaign by people who believe that the small amount of mercury in thiomersal can cause autism.

Legislators across the political spectrum voted almost unanimously for the ban on 15 January (85 votes in favour and five abstentions) despite consensus among international scientists and doctors that this kind of vaccine is safe.

If it is signed into law by the president, the bill would make Chile the only country to ban vaccines containing thiomersal, which are used worldwide in …
Vision screening in children tested at 7, 11, and 16 years.
Authors: A D Tibbenham, C S Peckham, P A Gardiner
Journal: BMJ (1978)

Distant vision screenings of a national sample of children were performed at the ages of 7, 11, and 16. Many children with normal vision at one screening showed defects at later screenings, and altogether 18% of children with normal vision at the age of 7 had defects by the time they were 16. Twelve per cent of those with normal vision at 7 and 11 had developed a visual defect by the age of 16. Apparent improvements between screenings probably resulted largely from technical difficulties inherent in testing young children. The results clearly indicate the importance of regular vision screening during the school years and the need for comprehensive but flexible back-up services.
Headliners: Neurodevelopment: Genomewide Screen Reveals Candidate Genes for Neural Tube Defects
Authors: Jerry Phelps
Journal: Environmental Health Perspectives (2006)

Nearly 10 years ago, researchers with the National Toxicology Program (NTP) and the National Center for Toxicological Research (NCTR) began a complex set of experiments in rats to determine whether exposure to estrogenic compounds throughout life and across generations could cause changes in development or patterns of endocrine-related cancers at doses that cause only subtle reproductive effects.Now, at last, specialists in the field of endocrine-active chemicals are close to getting a first look at the findings from these studies.The three compounds chosen for study-genistein, ethinyl estradiol, and p-nonylphenol-represent a natural estrogenic substance, a drug, and an industrial chemical, respectively.The first experiments for all three compounds focused on determining appropriate dose ranges for later multigenerational studies.Additionally, studies were conducted with genistein and ethinyl estradiol to determine whether and how the carcinogenic potential of these substances changed across generations following long-term chronic exposure.On 12 June 2006, the first reports based on these experiments will undergo peer review at a one-day meeting at the NIEHS, with final publication expected later this year and additional reports scheduled for review in 2007.The reports to be reviewed on June 12 center on genistein, an estrogen-like compound found in soy, and detail the results of dose range-finding studies and multigenerational reproductive and carcinogenesis experiments.
Nebivolol, a Vasodilating Selective β1-Blocker, Is a β3-Adrenoceptor Agonist in the Nonfailing Transplanted Human Heart
Authors: Bertrand Rozec, Mortéza Erfanian, Karine Laurent, Jean-Noël Trochu, Chantal Gauthier
Journal: Journal of the American College of Cardiology (2009)
Effects of a bisphosphonate (1-hydroxy ethylidene-1,1 bisphosphonic acid) on osteoclast number during prolonged bed rest in healthy humans
Authors: D. Chappard, C. Alexandre, S. Palle, L. Vico, B.V. Morukov, S.S. Rodionova, P. Minaire, G. Riffat
Journal: Metabolism (1989)
Ornithine Transcarbamylase Deficiency
Authors: Thomas D. Gelehrter, Leon E. Rosenberg
Journal: New England Journal of Medicine (1975)

ORNITHINE transcarbamylase (OTC), the second enzyme in the Krebs—Henseleit urea cycle, catalyzes the formation of citrulline from ornithine and carbamyl phosphate in hepatic mitochondria. Inherited, virtually complete deficiency of OTC causes lethal neonatal hyperammonemia in affected male infants.1 , 2 Orotic aciduria is also observed in these patients, presumably because carbamyl phosphate accumulates behind the block, enters the cytoplasm, and serves as a substrate for pyrimidine biosynthesis.2 , 3 All previous attempted therapeutic measures, including oral antibiotics, enemas, lactulose, peritoneal dialysis, and exchange transfusion, have been unsuccessful in altering the uniformally fatal outcome in these newborn male infants.1 , 2 We report here an unsuccessful attempt . . .
Evaluation of Response to Multikinase Inhibitor in Metastatic Renal Cell Carcinoma by FDG PET/Contrast-Enhanced CT
Authors: Ryogo Minamimoto, Noboru Nakaigawa, Ukihide Tateishi, Akiko Suzuki, Kazuya Shizukuishi, Takeshi Kishida, Takeshi Miura, Kazuhide Makiyama, Masahiro Yao, Yoshinobu Kubota, Tomio Inoue
Journal: Clinical Nuclear Medicine (2010)

Multikinase inhibitor (MKI) is a promising drug for treatment of metastatic renal cell carcinoma (mRCC). We explained the usefulness of [¹⁸F]-2-fluoro-2-deoxyglucose positron emission tomography/contrast-enhanced computed tomography (FDG PET/CECT) for mRCC in evaluating the early response to MKI and in predicting progression-free survival (PFS).Patients who planned MKI treatment for mRCC were included in this prospective study. FDG PET/CECT was performed before MKI treatment and after one cycle of MKI treatment. Evaluation of the response to MKI was assessed by PET according to the European Organization for Research and Treatment of Cancer, by CT according to the Response Evaluation Criteria in Solid Tumors and appearance of central hypoattenuation (CHA).Twelve patients were enrolled in the study. Equality of response evaluation between PET and CT was in 8 patients (partial response [PR]: 1, stable disease [SD]: 6, progressive disease [PD]: 1). Among the other 4 patients, PET showed 2 patients with PR and 2 patients with PD, in contrast to the CT finding of SD in all 4 patients. PFS according to PET response showed a statistically significant difference between PR and SD (P < 0.05) and between PR and PD (P < 0.05), but not between PR and SD (P = 0.083). Positive CHA in metastatic lesions after MKI treatment was confirmed in 8 patients. PFS with positive CHA was 233.8 days, while that without CHA was 75.0 days (P < 0.05).FDG PET/CECT shows potential for evaluating early treatment response to MKI in mRCC and for predicting PFS.
TCT-145 Do Baseline Hemoglobin And Hematocrit Influence The On-Treatment Platelet Reactivity To Clopidogrel Measured By The VerifyNow P2Y12 Assay?
Authors: lakshmana Pendyala, Israel Barbash, Kenneth Kent, Hironori Kitabata, Joshua P. Loh, Marco A. Magalhaes, Sa'ar Minha, Alfazir Omar, Hideaki Ota, Augusto Pichard, Lowell F. Satler, William O. Suddath, Rebecca Torguson, Ron Waksman
Journal: Journal of the American College of Cardiology (2013)
A pivotal role of cytosolic phospholipase A2 in bleomycin-induced pulmonary fibrosis
Authors: Takahide Nagase, Naonori Uozumi, Satoshi Ishii, Yoshihiro Kita, Hiroshi Yamamoto, Eijiro Ohga, Yasuyoshi Ouchi, Takao Shimizu
Journal: Nature Medicine (2002)
Treatment of hypertension with propranol.
Authors: F. J. Zacharias
Journal: BMJ (1969)

MEDICBALJOURNALcare, who was taking 300 mg. per day of chlorpromazine, collapsed in a hypothermic state while swimming in a public swimmingbath.Rewarming and resuscitation produced complete recovery.The possible hazard of hypothermia and respiratory distress due to swimming in patients taking phenothiazine drugs is not generally recognized, and would merit further laboratory and clinical investigation.-Iam, etc.,
Under the Crystal Eye
Authors: BERNADINE Z. PAULSHOCK
Journal: Annals of Internal Medicine (1979)

Ad Libitum1 August 1979Under the Crystal EyeBERNADINE Z. PAULSHOCK, M.D.BERNADINE Z. PAULSHOCK, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-91-2-313_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptVegetable cells in sputum specimens collected shortly following meals may be confusing. One distinguishing feature is the presence of the cellulose membrane of plant cells which creates a double-walled appearance.Under the crystal eye, the differenceBetween an onion and a man is small:Around the one's a wall;The plant's the one on guard.Without 1200X, reverse is true:Onions are bare, and flowers;So is grass.It's people who have sets of walls.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Wilmington, Delaware PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1979Volume 91, Issue 2Page: 313-313KeywordsCellsSputum ePublished: 1 December 2008 Issue Published: 1 August 1979 PDF downloadLoading ...
869-1 Relationship between time to reperfusion, ST-segment resolution, myocardial blush scores and mortality with primary percutaneous coronary intervention for acute myocardial infarction: Results from the CADILLAC trial
Authors: Bruce R Brodie, Costantino Costantini, Eve Aymong, Thomas D Stuckey, David A Cox, Peter Zimetbaum, Michael McLaughlin, Eulogio Garcia, Mark A Turco, Roxana Mehran, Cindy L Grines, Alexandra J Lansky, Gregg Stone
Journal: Journal of the American College of Cardiology (2004)
Alcohol Ingestion and Muscle Spasms
Authors: Nathan K. Blank
Journal: JAMA (1979)

To the Editor.—  The discussion of alcohol ingestion and leg cramps in QUESTIONS AND ANSWERS (240:2196, 1978) fails to mention two other conditions where alcohol-induced severe muscle spasms occur. The first disorder is a hereditary syndrome that has prominent and generalized muscle spasms including in the face and tongue; it lasts for a few minutes to several hours and is induced by fatigue, tension, cold, and alcohol.1Electromyographic (EMG) recordings of muscles in spasm disclose normal motor unit activity.  The second disorder was described in a 20-year-old woman in whom painful muscle cramping developed after she had ingested alcohol.2The muscle spasms lasted 12 to 24 hours, and EMG recordings taken both before and after alcohol administration disclosed persistent motor unit activity at rest and even during sleep; but the EMG activity was abolished by spinal anesthesia, peripheral nerve block, and procaine hydrochloride infiltration into the muscle. The
AMA Awards for Continuing Medical Education
Authors: Greg Buhmian
Journal: JAMA (1971)

<h3>To the Editor.—</h3> I recently received application forms for the 1970 American Medical Association Physician Recognition Award for participation in continuing medical education. The program places emphasis upon formal education activities but gives no credit to the physician involved in self-directed study. I suggest extension of the accreditation scheme to encompass a wider range of educational activities. It might be organized as follows. Physicians could be supplied with books similar to those given to consumers for keeping trading stamps. Stamps to be affixed in these books would be given to physicians for participating in educational pursuits. Those charged with the responsibility of organizing approved formal education courses would give stamps to physicians in attendance; the number of stamps to be given would be dependent upon the number of hours for which the course was accredited. Lecturers would receive more stamps than physicians who merely attend. Medical books might have attached
Rat hair follicle growth in vitro
Authors: M.P. PHILPOTT, M.R. GREEN, T. KEALEY
Journal: British Journal of Dermatology (1992)

Journal Article Rat hair follicle growth in vitro Get access M.P. PHILPOTT, M.P. PHILPOTT Department of Clinical Biochemistry, University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QR, U.K. Dr M. P. Philpott. Search for other works by this author on: Oxford Academic Google Scholar M.R. GREEN, M.R. GREEN Unilever Research, Colworth House, Sharnbrook, Bedford MK44 1LQ, U.K. Search for other works by this author on: Oxford Academic Google Scholar T. KEALEY T. KEALEY Department of Clinical Biochemistry, University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QR, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 127, Issue 6, 1 December 1992, Pages 600–607, https://doi.org/10.1111/j.1365-2133.1992.tb14873.x Published: 01 December 1992
Denial in the Medical Interview-Reply
Authors: Jack Ende
Journal: JAMA (1995)

<h3>In Reply.</h3> —We completely agree with Dr Moon that physicians exhibit denial and that self-knowledge in this area benefits the medical encounter. As we discussed in example number 3, which illustrates collusion in denial between a patient and a physician, "Denial does not necessarily 'belong' exclusively to either party." Can physicians learn to recognize and cope with their own denial, as Dr Moon advises? One method is to start by becoming aware of one's own blind spots, such as revulsion toward child abuse or domestic violence; this may be an important step for the physician toward avoiding denial when having to deal with these problems in the clinical setting. We believe that there is also a cognitive aspect to denial: "When faced with a choice, a rational decision-maker will prefer the prospect that offers the highest expected utility."<sup>1</sup>Physicians are less likely to deny or avoid a clinical problem
Anticoagulants Plus Streptokinase Therapy in Progressive Stroke
Authors: John S. Meyer, John Gilroy, Marion I. Barnhart, J. Frederic Johnson
Journal: JAMA (1964)

AN ATTEMPT to lyse intravascular thrombi in progressive cerebral thrombosis seemed to be a method of treatment worth investigating. It was hoped to restore blood flow to the ischemic area of the brain before irreversible infarction had occurred. Several methods are presently available for induction of an active thrombolytic state in patients with progressive strokes. One method, the intravenous infusion of streptokinase-activated human plasminogen, has already been studied in our neurological unit.<sup>1,2</sup>No statistical difference in the clinical outcome was noted between those treated with plasmin and those who did not receive the preparation. The present study was designed to investigate the possible usefulness of streptokinase ( SK ) in progressive strokes. <h3>Material and Methods</h3> All of the 73 patients admitted to this study had progressive stroke treated within 72 hours of its onset. To reduce the risk of treating intracerebral hemorrhage or producing hemorrhage, patients were selected with a clear
Abstract P5-11-09: Crk II adaptor proteins as positive regulators of HER3 signaling in breast cancer
Authors: P Dhupkar, H Zhao, S Mukherjee, K Mujoo, N Zhang, Z An
Journal: Cancer Research (2013)

Abstract HER3 (ErbB3), which is a member of the human epidermal growth factor receptor (EGFR) family has emerged as a key oncogene in cancer progression. HER3 overexpression has been observed in lung, prostate, melanomas and colon cancers and is associated with poor patient prognosis. HER3 has been known to play a role in resistance mechanisms towards EGFR tyrosine kinase inhibitors like Gefitinib and anti-HER2 antibodies like Trastuzumab in lung and breast cancers respectively. Upon ligand (neuregulin) binding, HER3 heterodimerizes with its partner receptors, inducing phosphorylation of its tyrosine residues in the c-terminal tail, which mediate HER3-dependent signaling. By binding to the HER3 c-terminal tail, Src homology 2 domain (SH2) or phosphotyrosine-binding (PTB) proteins may regulate the neuregulin-induced signaling. Here, we used a SH2 profiling approach to discover novel SH2 adaptor proteins interacting with HER3 and found that the SH2 adaptor protein Crk II (C10 regulator of kinase II) interacts strongly with phosphotyrosines in CHO cells overexpressing HER3 with or without neuregulin stimulation. Crk II and HER3 are critical in proliferation, migration and invasion of breast cancer cells. In this study, we investigate the protein-protein interaction of Crk II and HER3 in breast cancer. Our preliminary protein-protein interaction data confirmed that Crk II interacts with HER3 in MCF-7, MDA-MB-453 and MDA-MB-468 breast cancer cells. We hypothesize that Crk II affects HER3-induced signaling, thus affecting growth and migration in breast cancer cells. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-11-09.